We are excited to announce that we have recently partnered with InVision Medical Technology to bring its artificial intelligence (AI) algorithms to Australia & New Zealand. 

InVision develops AI tools to streamline the interpretation of heart ultrasounds and identify undiagnosed disease. HeartLab’s cloud-based platform for cardiac imaging is already a core part of the workflow for many cardiology teams across Australia & New Zealand. Their new partnership will be the first time this technology is available in the region.

This agreement will make available AI-based detection of cardiac amyloidosis and assessment of heart function for early detection and treatment of heart failure for the thousands of scans that are recorded in HeartLab each week. 

HeartLab’s CEO Will Hewitt says the partnership with InVision is an exciting opportunity to bring cutting edge technology to heart care in the region. 

“Historically advanced new medical technologies have taken years to become available, particularly in places like New Zealand which are not major markets for medical device companies. It’s exciting to be able to bring this cutting edge technology to the hundreds of people that log into HeartLab each day.” says Hewitt.

InVision’s CEO Dr David Ouyang says “We are excited to partner with HeartLab’s innovative cardiology imaging platform to democratize access to next-generation artificial intelligence diagnostic testing. Echocardiography, as the most common form of cardiac imaging, is a vital opportunity for early disease detection. As a rare form of heart failure, cardiac amyloidosis is frequently missed in routine care, and AI can serve as a ‘safety-net’ for uncommon disease detection.”

The technology will become available pending regulatory approval in Australia and New Zealand, which the companies hope will be in the first half of 2026. InVision Precision Cardiac Amyloid and Precision LVEF is already FDA cleared in the United States. 

‍